Literature DB >> 1904721

Restoration of arylsulphatase B activity in human mucopolysaccharidosis-type-VI fibroblasts by retroviral-vector-mediated gene transfer.

C Peters1, W Rommerskirch, S Modaressi, K von Figura.   

Abstract

The Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI; MPS VI) is a lysosomal storage disease caused by deficiency of the enzyme arylsulphatase B (ASB). A human ASB cDNA has been subcloned into the retroviral vector pXT1 containing the bacterial neomycin-resistance gene and an internal thymidine kinase promoter for transcription of the inserted gene. Replication defective retrovirus was generated by transfecting the construct into the amphotropic packaging cell line PA317. Human MPS VI fibroblasts infected with recombinant retrovirus integrated the provirus into their genome and expressed retrovirus-encoded ASB mRNAs. In infected fibroblasts the level of ASB was up to 36-fold higher than in normal fibroblasts. Biosynthesis and processing of ASB in infected MPS VI fibroblasts was accomplished as in normal fibroblasts, and mature, enzymically active, ASB accumulated in dense lysosomes, indicating that the ASB deficiency in MPS VI fibroblasts was corrected by the retroviral gene transfer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904721      PMCID: PMC1151119          DOI: 10.1042/bj2760499

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease.

Authors:  J K Fink; P H Correll; L K Perry; R O Brady; S Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

2.  Human N-acetylgalactosamine-4-sulphatase biosynthesis and maturation in normal, Maroteaux-Lamy and multiple-sulphatase-deficient fibroblasts.

Authors:  J A Taylor; G J Gibson; D A Brooks; J J Hopwood
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

3.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.

Authors:  A D Miller; C Buttimore
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

4.  Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors.

Authors:  G Keller; C Paige; E Gilboa; E F Wagner
Journal:  Nature       Date:  1985 Nov 14-20       Impact factor: 49.962

5.  Correction of feline arylsulphatase B deficiency (mucopolysaccharidosis VI) by bone marrow transplantation.

Authors:  P W Gasper; M A Thrall; D A Wenger; D W Macy; L Ham; R E Dornsife; K McBiles; S L Quackenbush; M L Kesel; E L Gillette
Journal:  Nature       Date:  1984 Nov 29-Dec 5       Impact factor: 49.962

6.  Efficient retrovirus-mediated transfer and expression of a human adenosine deaminase gene in diploid skin fibroblasts from an adenosine deaminase-deficient human.

Authors:  T D Palmer; R A Hock; W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

7.  Clonal gene therapy: transplanted mouse fibroblast clones express human alpha 1-antitrypsin gene in vivo.

Authors:  R I Garver; A Chytil; M Courtney; R G Crystal
Journal:  Science       Date:  1987-08-14       Impact factor: 47.728

8.  Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo.

Authors:  D A Williams; S H Orkin; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  Human arylsulfatase B: MOPAC cloning, nucleotide sequence of a full-length cDNA, and regions of amino acid identity with arylsulfatases A and C.

Authors:  E H Schuchman; C E Jackson; R J Desnick
Journal:  Genomics       Date:  1990-01       Impact factor: 5.736

View more
  7 in total

Review 1.  Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.

Authors:  Dao Pan
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

2.  Restoration of arylsulphatase A activity in human-metachromatic-leucodystrophy fibroblasts via retroviral-vector-mediated gene transfer.

Authors:  W Rommerskirch; A L Fluharty; C Peters; K von Figura; V Gieselmann
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

3.  Secondary storage of dermatan sulfate in Sanfilippo disease.

Authors:  William C Lamanna; Roger Lawrence; Stéphane Sarrazin; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

4.  Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy.

Authors:  C Fillat; C M Simonaro; P L Yeyati; J L Abkowitz; M E Haskins; E H Schuchman
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

5.  Multiple sulfatase deficiency: catalytically inactive sulfatases are expressed from retrovirally introduced sulfatase cDNAs.

Authors:  W Rommerskirch; K von Figura
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

6.  Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase.

Authors:  S E Braun; E L Aronovich; R A Anderson; P L Crotty; R S McIvor; C B Whitley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

7.  Overexpression of N-acetylgalactosamine-4-sulphatase induces a multiple sulphatase deficiency in mucopolysaccharidosis-type-VI fibroblasts.

Authors:  D S Anson; V Muller; J Bielicki; G S Harper; J J Hopwood
Journal:  Biochem J       Date:  1993-09-15       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.